Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level

The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.

The duration of treatment is 6 weeks.

Inclusion Criteria:

• High cholesterol levels that are identified by specific laboratory values

Exclusion Criteria:

• Active liver disease
• Any condition or situation which would interfere with participation